MagnetisMM-7: what clinicians are saying
elranatamab in newly diagnosed multiple myeloma after autologous stem-cell transplantation · NCT05317416 ↗ · Phase 3 · Pfizer
A medical oncologist reads MagnetisMM-7 as challenging maintenance practice, but considers Dara-R arguably more current than lenalidomide alone, with Isa-R only a possibility. In broader safety discussion, another speaker perceives more neuropathy, myalgias and skin reactions with elranatamab than with other bispecifics in practice; that oncologist cites broadly similar reported neurologic rates for elranatamab and teclistamab, noting prior-treatment confounding. The clinicians cited leave duration unresolved; neither comparison establishes maintenance-specific safety, and the sources reviewed for this edition provide no trial outcomes.
Created with AI · how we check it
- edition 1
- commentary checked Nov 22, 2026
- 34 verified statements
This edition $750, with MCP access for your AI agent. Get this report
5 findings, and what sits behind each
01. Lenalidomide alone: why a clinician questions the post-ASCT maintenance comparator
1 of the report's 3 cited clinicians · 4 statements from 2 speakers in 3 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 2.
Draws on: The comparison.
02. Maintenance: most clinicians ask how long; one asks about OS and sequencing
2 of the report's 3 cited clinicians · 7 statements from 3 speakers in 4 sources, 2 of them podcasts or videos · 6 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, Primary endpoint: Progression Free Survival, Population and setting, The comparison, Safety and tolerability.
03. Earlier use: a speaker weighs durability vs toxicity; a clinician supports trials
1 of the report's 3 cited clinicians · 8 statements from 2 speakers in 2 sources, all podcasts or videos · 5 passages
Limitations recorded: 5.
Draws on: Population and setting.
Beyond the trial population
04. Elranatamab: where speakers split on relative neuropathy risk
1 of the report's 3 cited clinicians · 5 statements from 2 speakers in 1 source · 2 passages
Limitations recorded: 3.
05. Local care: what speakers say
No named clinician · accounts and unnamed speakers · 7 statements from 1 speaker in 1 source, a podcast or video · 3 passages
Limitations recorded: 4.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 5
1 of the report's 3 cited clinicians
Lenalidomide alone: why a clinician questions the post-ASCT maintenance comparator
4 statements from 2 speakers in 3 sources, 1 of them a podcast or video
1 of the 2 named speakers in this finding holds this view, a confirmed clinician
- 4
- statements
- 5
- passages
- 3
- sources
- 2
- speakers
What the statements areViews 1Questions and uncertainty 1Clinical experience 0Comparisons 1Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 5Giving context 2Recorded with the findingLimitations: 2
1 post or article · 1 podcast or video · 1 registry
Draws on: The comparison.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 5 findings and 12 of the 34 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (4)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival.
The full MagnetisMM-7 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say about whether lenalidomide alone remains the right comparator for elranatamab maintenance in MagnetisMM-7 after autologous transplantation in newly diagnosed multiple myeloma, versus daratumumab–lenalidomide or possibly isatuximab–lenalidomide?
From finding F1 (4 statements from 2 speakers in 3 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 13commentary sources screened
- 6sources cited by verified statements
- 6named in screened sources
- 6speakers cited in the report
- 5cited speakers with a verified identity
3 cited clinicians, speakers with a confirmed clinical role, of them 3 physicians. By role and specialty:
- 2 physician, Medical oncology
- 1 physician, Hematology and oncology
- 34verified statements, each linked to its source
- 9of them from speakers with a confirmed clinical role
- 5findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Who said each statement: the cited speakers | 6 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 9 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
8 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression Free Survival | 2 | 2 |
| Secondary endpoints | 3 | 2 |
| Population and setting | 4 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 4 | 3 |
| Safety and tolerability | 6 | 2 |
| Design and conductno commentary found | 0 | 0 |
| Treatment duration, placement and sequencing | 2 | 2 |
| Earlier-use and cross-study development rationale | 3 | 2 |
| Community delivery and patient-support constraints | 7 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
34 verified statements from 6 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 25 statements · 74% | ||||
| YouTube | 25 | 4 | 4 | |
| Podcasts | 0 | 0 | 1 | |
| Posts · 8 statements · 23% | ||||
| X threads | 8 | 1 | 8 | |
| Primary sources · 1 statement · 3%cited for context, not screened | ||||
| Registry | 1 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 2 / quarter
- Screened window
- Apr 8, 2022 → Nov 1, 2026
- Cited window
- Oct 6, 2022 → Nov 1, 2026
- Retrieved
- Nov 22, 2026
The trial
from ClinicalTrials.gov- Title
- A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
- Registry
- NCT05317416
- Study IDs
- C1071007 · MagnetisMM-7 (Alias Study Number) · 2023-508897-27-00 (CTIS (EU))
- Sponsor
- Pfizer
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 854 actual
- Registered
- 2022-04-07
- Start
- 2022-03-25 actual
- Primary completion
- 2027-08-04 estimated
- Primary endpoint
- Progression Free Survival
- Interventions
- 4 registered
More on: Multiple myeloma, elranatamab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 38 sources about other trials or topics are not included; discussion that refers to the trial only by a name it shares with other things may be missing.
- The sources reviewed for this edition are selected public discussions, not a representative sample of HCP opinion. One X thread and four video sources underpin this narrative; multiple statements or reposts should not be counted as independent clinicians.
- Discussion that does not name the trial, uses short acronyms or contains other transcription variants may be missing. An issue not discussed here may nevertheless be discussed elsewhere.
Show all 10 known gaps +Fewer −
- A standalone protocol document and an exact-trial publication were not identified for this edition. The materials do not provide MagnetisMM-7 outcome data with which to test the expressed expectations or concerns.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The comparative safety impressions and reported neurologic rates lack sufficient population, timing and study detail to establish comparative safety in post-transplant maintenance.
- Some panel remarks cannot be assigned to a named speaker and may have been made by a named participant already represented elsewhere in the discussion.
- General earlier-line and community-delivery observations do not establish MagnetisMM-7 efficacy, toxicity rates, dosing schedules or service requirements.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 22, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. MagnetisMM-7 (NCT05317416): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/magnetismm-7-nct05317416
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "MagnetisMM-7" (NCT05317416), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "magnetismm-7-nct05317416". If you cannot make requests, read https://www.erudio.com/reports/magnetismm-7-nct05317416.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05317416", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05317416 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/magnetismm-7-nct05317416.json
curl https://www.erudio.com/reports/magnetismm-7-nct05317416.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "magnetismm-7-nct05317416" })release 67a580e655dd94086b2777c68ef0b6e36c11f74c1d88be464fe53470aa8c8979
Questions
How much does the MagnetisMM-7 report cost?
One edition costs $750 (Focused · 34 verified statements · 9 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the MagnetisMM-7 report cover?
34 statements from 6 sources (4 videos, 1 post, 1 registry record), 9 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the MagnetisMM-7 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "magnetismm-7-nct05317416" }) previews it and create_order({ "report": "magnetismm-7-nct05317416", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the MagnetisMM-7 report?
Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.